Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
The presence of anti-ENA and anti-dsDNA autoantibodies in SLE patients was associated with elevated levels of TLR7 and TLR9 respectively.
|
23564191 |
2013 |
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) patients have anti-nuclear autoantibodies directed against dsDNA and RNA-associated antigens (extractable nuclear antigens; ENA).
|
24659206 |
2014 |
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
These results might suggest that Italian patients with SLE are, at least in part, different from lupus patients living in other geographical areas and suggest the association of DQw2 with the autoantibody response to ENA in SLE.
|
1954698 |
1991 |
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
ACA = anti-cardiolipin antibodies; ANF = anti-nuclear factor; anti-CCP = anti-cyclic citrullinated peptide; anti-dsDNA = anti-double-stranded DNA; anti-RNP = anti-ribonucleoprotein; anti-Scl70 = anti-topoisomerase I antibodies; anti-SM = anti-Smith antigen antibodies; anti-SS-A/Ro = anti-Sjögren syndrome-related antigen A (Ro); anti-SS-B/La = anti-Sjögren syndrome-related antigen B (La); anti-Tg = anti-thyroglobulin; anti-TPO = anti-thyroid peroxidase; ATD = autoimmune thyroid disease; ENA = extractable nuclear antigen; fT4 = free thyroxine; OR = odds ratio; RF = rheumatoid factor; SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index; TD = thyroid dysfunction; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine.
|
28816533 |
2017 |
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
Anti-dsDNA antibodies were higher in SLE and ENA showed the highest titers in MCTD.
|
30807792 |
2019 |
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The Mena protein expression level was analyzed in paraffin-embedded GC samples and adjacent normal tissues by immunohistochemistry.
|
29113241 |
2017 |
Stomach Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PPARγ might inhibit the proliferation and migration of GC cell lines through suppressing the expression of TERT and ENAH.
|
26956036 |
2016 |
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our research suggests that ENAH might play promoting functions in carcinogenesis and progression of gastric cancer, and may serve as a valuable prognostic marker for primary gastric adenocarcinoma patients.
|
29069803 |
2017 |
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Knockdown of ENAH expression suppressed cell proliferation, colony formation, cell migration and invasion in MKN45 cells.
|
29069803 |
2017 |
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our study provides a novel mechanism that PTBP1 modulates Mena exon11a skipping, and indicates that PTBP1 depends on the level of Mena11a- to promote lung cancer cells migration and invasion.
|
31075540 |
2019 |
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
Tumor Cell Invasion
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
The possible role of Mena protein and its splicing-derived variants in embryogenesis, carcinogenesis, and tumor invasion: a systematic review of the literature.
|
23956979 |
2013 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression of ENAH isoform 11a has been shown to be elevated in breast cancers that express HER2.
|
26149387 |
2015 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).
|
25670169 |
2015 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival.
|
26811325 |
2016 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Recent studies show overexpressed ENAH in several cancer types, and ENAH correlates with tumor invasiveness.
|
29069803 |
2017 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
This study aimed to investigate the oncogenic potential of MENA and its capacity to regulate cancer stem cell (CSC)-like phenotypes in HCC cells.
|
28781954 |
2017 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A typical sequencing study can easily generate hundreds of gigabytes of FASTQ files, while public archives such as ENA and NCBI and large international collaborations such as the Cancer Genome Atlas can accumulate many terabytes of data in this format.
|
24950811 |
2014 |
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our research suggests that ENAH might play promoting functions in carcinogenesis and progression of gastric cancer, and may serve as a valuable prognostic marker for primary gastric adenocarcinoma patients.
|
29069803 |
2017 |
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
PPARγ might inhibit the proliferation and migration of GC cell lines through suppressing the expression of TERT and ENAH.
|
26956036 |
2016 |
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Human ortholog of mammalian enabled (Mena) is a conserved regulator of actin dynamics that plays an important role in metastasis.
|
31075540 |
2019 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The actin regulatory protein MENA and particularly its invasive isoform, MENA<sup>INV</sup>, are established drivers of metastasis.
|
27811011 |
2017 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |